14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0060 $169.56 Friday, 27th Jan 2023 GBT stock ended at $68.49. During the day the stock fluctuated 0% from a day low at $68.49 to a day high of $68.49.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical GLOBAL BLOOD THERAPEUTICS prices

Date Open High Low Close Volume
Mar 23, 2016 $16.05 $16.15 $14.87 $15.00 312 300
Mar 22, 2016 $15.61 $16.54 $15.57 $16.12 208 900
Mar 21, 2016 $15.58 $16.08 $15.31 $15.83 119 100
Mar 18, 2016 $15.39 $15.94 $14.81 $15.62 374 800
Mar 17, 2016 $15.98 $16.04 $15.19 $15.27 172 300
Mar 16, 2016 $15.69 $16.11 $15.51 $15.98 164 000
Mar 15, 2016 $16.51 $17.23 $15.51 $15.77 237 400
Mar 14, 2016 $15.91 $17.26 $15.83 $16.67 140 700
Mar 11, 2016 $15.29 $16.49 $15.25 $16.02 195 700
Mar 10, 2016 $15.74 $16.53 $14.68 $15.06 283 600
Mar 09, 2016 $16.19 $16.46 $15.36 $15.58 164 900
Mar 08, 2016 $17.50 $17.62 $15.80 $16.08 245 300
Mar 07, 2016 $16.41 $17.70 $16.26 $17.70 240 500
Mar 04, 2016 $16.06 $16.54 $15.00 $16.45 433 000
Mar 03, 2016 $15.62 $16.51 $15.61 $16.00 263 000
Mar 02, 2016 $14.76 $15.98 $14.62 $15.57 316 200
Mar 01, 2016 $15.08 $15.19 $14.63 $15.01 232 300
Feb 29, 2016 $14.88 $15.35 $14.52 $14.93 196 200
Feb 26, 2016 $15.03 $15.51 $14.55 $14.87 205 200
Feb 25, 2016 $15.10 $15.94 $14.56 $14.93 294 900
Feb 24, 2016 $15.30 $15.30 $14.78 $14.96 186 300
Feb 23, 2016 $16.05 $16.97 $15.37 $15.53 278 400
Feb 22, 2016 $16.81 $17.20 $16.26 $16.30 190 800
Feb 19, 2016 $17.06 $17.55 $16.48 $16.70 192 700
Feb 18, 2016 $17.56 $17.65 $16.93 $17.15 210 700
Click to get the best stock tips daily for free!

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... GBT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT